PIOL suitable for myopic eyes

Article

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

Dr Omid Kermani et al., Augenklinik am Neumarkt, Cologne, Germany, evaluated the rotational stability of the PIOL 12 months after implantation in fifty eyes of 28 patients with myopia. Digital overlay of the ocular photographs, taken within two weeks of implantation, were used to assess IOL rotation.

The secondary outcomes included spherical equivalent, refractive sphere and cylinder, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). All measurements were analysed preoperatively and three months after implantation.

All patients underwent successful IOL implantation and follow-up. The outcomes presented a mean 12-month rotation of 11º and only 2% of eyes required additional laser adjustment by month 12, due to corneal astigmatism.

Outcomes improved at the three-month follow-up, with spherical equivalent at 0.35 ± 0.79 D, spherical refraction at 0.04 ± 0.82 D and cylindrical refraction at −0.77 ± 0.91 D.

Overall, the lens effectively corrects myopia but the rotation means it is unsuitable for cylinder correction.

The abstract can be viewed in the latest issue of the Journal of Refractive Surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.